Neuroprotective Effect of Lentivirus-Mediated FGF21 Gene Delivery in Experimental Alzheimer’s Disease is Augmented when Concerted with Rapamycin

• Published in: Molecular neurobiology 2022-05, Vol.59 (5), p.2659-2677
• Main Authors: Kakoty, Violina, C, Sarathlal K, Yang, Chih-Hao, Kumari, Shobha, Dubey, Sunil Kumar, Taliyan, Rajeev
• Format: Article
• Language: English
• Subjects: Alzheimer Disease - complications; Alzheimer Disease - drug therapy; Alzheimer Disease - genetics; Alzheimer's disease; Amyloid beta-Peptides - metabolism; Animals; Autophagy; Biomedical and Life Sciences; Biomedicine; Cell Biology; Cognitive ability; Dementia disorders; Fibroblast Growth Factors; Gene transfer; Humans; Immunofluorescence; Lentivirus - genetics; Lentivirus - metabolism; Neurobiology; Neurodegenerative diseases; Neurology; Neuroprotection; Neuroprotective Agents - pharmacology; Neuroprotective Agents - therapeutic use; Neurosciences; Oxidative stress; Pathology; Plaque, Amyloid; Plaques; Rapamycin; Rats; Sirolimus - pharmacology; Sirolimus - therapeutic use; Supplements; Tau protein
• ISSN: 0893-7648; 1559-1182
• DOI: 10.1007/s12035-022-02741-6

Alzheimer type of dementia is accompanied with progressive loss of cognitive function that directly correlates with accumulation of amyloid beta plaques. It is known that Fibroblast growth factor 21 (FGF21), a metabolic hormone, with strong neuroprotective potential, is induced during oxidative stress in Alzheimer’s disease. Interestingly, FGF21 cross-talks with autophagy, a mechanism involved in the clearance of abnormal protein aggregate. Moreover, autophagy activation by Rapamycin delivers neuroprotective role in Alzheimer’s disease. However, the synergistic neuroprotective efficacy of overexpressed FGF21 along with Rapamycin is not yet investigated. Therefore, the present study examined whether overexpressed FGF21 along with autophagy activation ameliorated neurodegenerative pathology in Alzheimer’s disease. We found that cognitive deficits in rats with intracerebroventricular injection of Amyloid beta 1 - 42 oligomers were restored when injected with FGF21-expressing lentiviral vector combined with Rapamycin. Furthermore, overexpression of FGF21 along with Rapamycin downregulated protein levels of Amyloid beta 1 - 42 and phosphorylated tau and expression of major autophagy proteins along with stabilization of oxidative stress. Moreover, FGF21 overexpressed rats treated with Rapamycin revamped the neuronal density as confirmed by histochemical, cresyl violet and immunofluorescence analysis. These results generate compelling evidence that Alzheimer’s disease pathology exacerbated by oligomeric amyloid beta may be restored by FGF21 supplementation combined with Rapamycin and thus present an appropriate treatment paradigm for people affected with Alzheimer’s disease. Graphical abstract